Company Filing History:
7 out of 15,504 
6 out of 90 
2 out of 19 Years Active: 2010-2024
Title: Katerina Akassoglou: Innovator in Biomedical Research
Introduction
Katerina Akassoglou is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of biomedical research, particularly in understanding and addressing the physiological effects of COVID-19. With a total of 13 patents to her name, her work has been instrumental in developing therapeutic agents and assays that can aid in medical research and treatment.
Latest Patents
One of her latest patents is titled "Animal model for SARS-CoV-2-spike induced coagulopathy." This invention describes an animal model that is useful for identifying therapeutic agents capable of inhibiting the physiological effects or symptoms of COVID-19 infection. The model addresses various complications, including inflammation, oxidative stress, fibrin deposition, blood-brain barrier breakdown, clotting, and vascular problems. Another significant patent is "Compositions and methods for in vitro assays of fibrin activity." This invention provides compositions that exhibit in vivo activity of fibrin in an in vitro setting. It includes methods for producing and using these compositions and assays, which are essential for screening test agents that modulate cell activation and signaling pathways associated with fibrin activity.
Career Highlights
Katerina has worked with esteemed institutions such as the University of California and the J. David Gladstone Institutes. Her research has focused on innovative solutions to complex biomedical challenges, showcasing her dedication to advancing medical science.
Collaborations
Throughout her career, Katerina has collaborated with notable colleagues, including Jae Kyu Ryu and Anke Meyer-Franke. These partnerships have further enriched her research and contributed to her success as an inventor.
Conclusion
Katerina Akassoglou stands out as a leading figure in biomedical innovation. Her patents and research efforts continue to pave the way for advancements in understanding and treating diseases, particularly in the context of COVID-19.